Ann: Dotz Secures A$0.3m to Expedite BioDotz Cannabis Adaptation, page-7

Slalom Capital, a Canadian private equity firm with extensive interests in the cannabis sector, will pay a non-refundable one-time payment to Dotz of A$296,000 within 60 days, to finalise the development of the BioDotz™ technology on cannabis plants over the nine months following the A$296,000 payment.Dotz will then grant Slalom exclusive rights to sell BioDotz in Canada, assuming annual wholesale targets are reached. The first annual wholesales target is A$370,000 (as income for Dotz).

The parties will then negotiate annual sales targets, consisting of at least the higher of: 125% of the prior year’s target; or 105% of the prior year’s actual sales.Should Slalom undertake an initial public offering or assign their rights under the agreement, 20 per cent of the equity in Slalom or the assignee entity will transfer to Dotz. The agreement also contemplates the parties entering a more formal licence and supply agreement upon completion of the development phase.Canada is the largest country in the world to have legalised medicinal and recreational cannabis.

Got to start somewhere fella's
If this dude floats it and we end up with 20% of the company.
They still have to purchase the GQD's off us. So will work out ok. The year on year % will compound. Actually glad someone in the top 20 is keen to commercialize a new technology. Its early days for the cannibliss market.
Everything starts off cheap when its unproven.